Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 6/20 | 0.54 |
| ▸ | MAOB | P27338 | 4/20 | 0.46 |
| ▸ | F10 | P00742 | 7/20 | 0.41 |
| ▸ | CALML3 | P27482 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | SDHA | P31040 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13855703 | 1.00 | MAOA (0.54) | MAOAMAOBF10CALML3LMNA | |
| SCHEMBL3028973 | 0.96 | MAOA (0.58) | MAOAMAOBF10CALML3LMNA | |
| SCHEMBL13855700 | 0.88 | MAOA (0.71) | MAOAMAOBF10CALML3LMNA | |
| SCHEMBL4240207 | 0.88 | MAOA (0.71) | MAOAMAOBF10CALML3LMNA | |
| SCHEMBL4543204 | 0.87 | MAOB (0.62) | MAOAMAOBF10CALML3LMNA | |
| SCHEMBL5512577 | 0.87 | MAOB (0.62) | MAOAMAOBF10CALML3LMNA | |
| SCHEMBL4380781 | 0.85 | MAOA (0.70) | MAOAMAOBF10CALML3LMNA | |
| SCHEMBL14639627 | 0.85 | MAOA (0.70) | MAOAMAOBF10CALML3LMNA | |
| SCHEMBL3048358 | 0.84 | MAOA (0.59) | MAOAMAOBF10CALML3LMNA | |
| SCHEMBL3029035 | 0.84 | MAOA (0.76) | MAOAMAOBF10CALML3LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137553-A1 | Thiazepine Oxazolidinones as Antibacterial Agents | PHARMACIA AND UPJOHN COMPANY LLC (US) | 2009-05-28 | — | — | US | claimed |
| US-20090137553-A1 | Thiazepine Oxazolidinones as Antibacterial Agents | PHARMACIA AND UPJOHN COMPANY LLC (US) | 2009-05-28 | — | — | US | disclosed |
| EP-1819702-A1 | THIAZEPINE OXAZOLIDINONES AS ANTIBACTERIAL AGENTS | Pharmacia & Upjohn Company LLC (US) | 2007-08-22 | — | — | EP | disclosed |
| WO-2006056875-A1 | THIAZEPINE OXAZOLIDINONES AS ANTIBACTERIAL AGENTS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2006-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137553-A1 | Thiazepine Oxazolidinones as Antibacterial Agents | OXA1L, TBCD, CLPP | MAOA 2869/4885MAOB 2947/4885F10 4548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.